Zoetis Inc. (ZTS): Price and Financial Metrics


Zoetis Inc. (ZTS)

Today's Latest Price: $162.57 USD

1.01 (0.63%)

Updated Jan 19 7:00pm

Add ZTS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ZTS Stock Summary

  • ZTS has a higher market value than 97.14% of US stocks; more precisely, its current market capitalization is $76,784,268,838.
  • With a one year PEG ratio of 394.53, Zoetis Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 90.69% of US stocks.
  • Price to trailing twelve month operating cash flow for ZTS is currently 38.59, higher than 87.77% of US stocks with positive operating cash flow.
  • If you're looking for stocks that are quantitatively similar to Zoetis Inc, a group of peers worth examining would be BDX, CI, SYK, ABB, and MDLZ.
  • Visit ZTS's SEC page to see the company's official filings. To visit the company's web site, go to www.zoetis.com.

ZTS Stock Price Chart Interactive Chart >

Price chart for ZTS

ZTS Price/Volume Stats

Current price $162.57 52-week high $176.64
Prev. close $161.56 52-week low $90.14
Day low $161.25 Volume 1,464,100
Day high $163.95 Avg. volume 1,791,755
50-day MA $162.94 Dividend yield 0.5%
200-day MA $150.26 Market Cap 77.26B

Zoetis Inc. (ZTS) Company Bio


Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey.

ZTS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$162.57$61.16 -62%

We started the process of determining a valid price forecast for Zoetis Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Zoetis Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Zoetis Inc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is 9.79 -- which is good for besting 70.06% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • ZTS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 35.41% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-63%
1%-63%
2%-62%
3%-62%
4%-61%
5%-61%

HAPP, PCRX, DYNT, HOLX, and LNTH can be thought of as valuation peers to ZTS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


ZTS Latest News Stream


Event/Time News Detail
Loading, please wait...

ZTS Latest Social Stream


Loading social stream, please wait...

View Full ZTS Social Stream

Latest ZTS News From Around the Web

Below are the latest news stories about Zoetis Inc that investors may wish to consider to help them evaluate ZTS as an investment opportunity.

Aquaculture Healthcare Market 2021 Focuses On Top Companies, Region And Opportunities Till 2027 | Zoetis, Archer Daniels Midland Company, Bayer Animal Health

Allied Market Research published a new report, titled, "Aquaculture Healthcare Market: Global Opportunity Analysis and Industry Forecast, 2020-2027". The report has offered an all-inclusive analysis of the global Aquaculture Healthcare Market taking into consideration all the crucial aspects like growth factors,

OpenPR | January 18, 2021

Zoetis Could Rally Further After Some More Sideways Consolidation

Buyers will need to be patient….ZTS

The Street RealMoney | January 14, 2021

GRFS or ZTS: Which Is the Better Value Stock Right Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Yahoo | January 12, 2021

Viral Vaccines Market to Witness Huge Growth by 2027| Key Players are GSK, Merck, Novartis, Pfizer, Sanofi, Bayer, Zoetis, AstraZeneca, Johnson and CSL

ReportsnReports.com the exclusive leading provider of market research reports published research report on “Global Viral Vaccines Market Research Report 2021”. The Global Viral Vaccines Market Report 2021 is a professional and in-depth study on the current state of the Viral Vaccines

OpenPR | January 8, 2021

Animal Genetic Market 2020: Current Trends And Future Aspect Analysis 2026 | Top Companies- Zoetis, Envigo, Animal Genetics Inc., VetGen, Groupe Grimaud

Data Bridge Market Research has recently added a concise research on the Global Animal Genetic Market to depict valuable insights related to significant market trends driving the industry. The Global Animal Genetic Market report is a window to the industry

OpenPR | January 4, 2021

Read More 'ZTS' Stories Here

ZTS Price Returns

1-mo -0.49%
3-mo 1.02%
6-mo 13.16%
1-year N/A
3-year 116.01%
5-year 289.99%
YTD -1.62%
2020 25.76%
2019 55.71%
2018 19.45%
2017 35.55%
2016 12.64%

ZTS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ZTS Dividend History

Continue Researching ZTS

Here are a few links from around the web to help you further your research on Zoetis Inc's stock as an investment opportunity:

Zoetis Inc (ZTS) Stock Price | Nasdaq
Zoetis Inc (ZTS) Stock Quote, History and News - Yahoo Finance
Zoetis Inc (ZTS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8447 seconds.